• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> Chimeric antigen receptor (CAR) constructs and disease treatment with T cells (CAR-T) or NK cells (CAR-NK) expressing CAR constructs

Chimeric antigen receptor (CAR) constructs and disease treatment with T cells (CAR-T) or NK cells (CAR-NK) expressing CAR constructs

机译：嵌合抗原受体（CAR）构建体以及表达CAR构建体的T细胞（CAR-T）或NK细胞（CAR-NK）的疾病治疗

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

The present invention preferably relates to CAR, CAR-T and CAR-NK constructs comprising scFv antibody fragments against disease associated antigens or haptens. More preferably, the antigen is a TAA, eg, Trop-2. The construct may be administered to a subject having a disease, such as a cancer, an autoimmune disease, or an immunodeficiency disease, to induce an immune response against the disease associated cells. If the construct binds to a hapten, the subject is first treated with a hapten conjugated antibody that binds to the disease associated antigen. The therapy may be supplemented with other treatments such as weight loss procedures (eg surgery, chemotherapy, radiation therapy) or co-administration of other agents. More preferably, administration of the construct is preceded by preadministration of unconjugated antibody that binds to the same disease associated antigen. Most preferably, antibodies to CD74 or HLA-DR are administered to reduce systemic immunotoxicity induced by the construct. [Selected figure] Figure 7
机译：本发明优选地涉及包含抗疾病相关抗原或半抗原的scFv抗体片段的CAR，CAR-T和CAR-NK构建体。更优选地，抗原是TAA，例如Trop-2。可以将构建体施用于患有疾病例如癌症，自身免疫疾病或免疫缺陷疾病的受试者，以诱导针对疾病相关细胞的免疫应答。如果构建体与半抗原结合，则首先用与疾病相关抗原结合的半抗原偶联抗体治疗受试者。该疗法可以补充其他疗法，例如减肥程序（例如手术，化学疗法，放射疗法）或其他药物的共同给药。更优选地，在给予构建体之前预先给予与相同疾病相关抗原结合的未结合抗体。最优选地，施用针对CD74或HLA-DR的抗体以减少由构建体诱导的全身免疫毒性。 [选定图]图7

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号